163 related articles for article (PubMed ID: 25738408)
1. Mast cells influence the proliferation rate of myeloma plasma cells.
Pappa CA; Tsirakis G; Stavroulaki E; Kokonozaki M; Xekalou A; Konsolas I; Alexandrakis MG
Cancer Invest; 2015 Apr; 33(4):137-41. PubMed ID: 25738408
[TBL] [Abstract][Full Text] [Related]
2. Positive correlation between bone marrow mast cell density and ISS prognostic index in patients with multiple myeloma.
Pappa CA; Tsirakis G; Roussou P; Xekalou A; Goulidaki N; Konsolas I; Alexandrakis MG; Stathopoulos EN
Leuk Res; 2013 Dec; 37(12):1628-31. PubMed ID: 24183234
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients.
Vyzoukaki R; Tsirakis G; Pappa CA; Devetzoglou M; Tzardi M; Alexandrakis MG
Int Arch Allergy Immunol; 2015; 168(4):263-8. PubMed ID: 26894886
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Mast Cell Density With Angiogenic Cytokines in Patients With Active Multiple Myeloma.
Vyzoukaki R; Tsirakis G; Pappa CA; Androulakis N; Kokonozaki M; Tzardi M; Alexandrakis MG
Clin Ther; 2016 Feb; 38(2):297-301. PubMed ID: 26740291
[TBL] [Abstract][Full Text] [Related]
5. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.
Alexandrakis MG; Passam FH; Dambaki C; Pappa CA; Stathopoulos EN
J Clin Pathol; 2004 Aug; 57(8):856-60. PubMed ID: 15280408
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.
Pappa CA; Tsirakis G; Devetzoglou M; Zafeiri M; Vyzoukaki R; Androvitsanea A; Xekalou A; Sfiridaki K; Alexandrakis MG
Tumour Biol; 2014 Jun; 35(6):5647-51. PubMed ID: 24563338
[TBL] [Abstract][Full Text] [Related]
7. High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.
Devetzoglou M; Vyzoukaki R; Kokonozaki M; Xekalou A; Pappa CA; Papadopoulou A; Alegakis A; Androulakis N; Alexandrakis MG
Tumour Biol; 2015 Nov; 36(11):8491-7. PubMed ID: 26026586
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.
Ribatti D; Vacca A; Nico B; Quondamatteo F; Ria R; Minischetti M; Marzullo A; Herken R; Roncali L; Dammacco F
Br J Cancer; 1999 Feb; 79(3-4):451-5. PubMed ID: 10027312
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
[TBL] [Abstract][Full Text] [Related]
10. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
Kumar S; Rajkumar SV; Greipp PR; Witzig TE
Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
[TBL] [Abstract][Full Text] [Related]
11. Mast cells contribute to vasculogenic mimicry in multiple myeloma.
Nico B; Mangieri D; Crivellato E; Vacca A; Ribatti D
Stem Cells Dev; 2008 Feb; 17(1):19-22. PubMed ID: 18205547
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.
Caers J; Van Valckenborgh E; Menu E; Van Camp B; Vanderkerken K
Bull Cancer; 2008 Mar; 95(3):301-13. PubMed ID: 18390410
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer.
Gulubova M; Vlaykova T
J Gastroenterol Hepatol; 2009 Jul; 24(7):1265-75. PubMed ID: 17645466
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of mast cells and angiogenesis in oral squamous cell carcinoma.
Sharma B; Sriram G; Saraswathi TR; Sivapathasundharam B
Indian J Dent Res; 2010; 21(2):260-5. PubMed ID: 20657098
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
19. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
20. Mast cells in acute cellular rejection of human renal allografts.
Lajoie G; Nadasdy T; Laszik Z; Blick KE; Silva FG
Mod Pathol; 1996 Dec; 9(12):1118-25. PubMed ID: 8972470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
